Ipca Laboratories Ltd
Ipca Laboratories Ltd (IPCALAB) last reported results for the quarter ended Jun 2026, with sales of ₹2,788 crore and net profit of ₹424 crore. The stock last traded at ₹1,936, a market capitalisation of ₹49,122 crore, on a P/E of 35.8. Over the past 52 weeks the stock has ranged between ₹1,252 and ₹2,039. Figures are as of 6 Oct 2026 and are not real time.
Ipca Laboratories Ltd share price and key metrics
- Current price
- ₹1,936
- Market cap
- ₹49,122 cr
- Stock P/E
- 35.8
- Book value
- ₹318
- ROE
- 15.7%
- ROCE
- 17.0%
- Dividend yield
- 0.31%
- 52w high / low
- 2039/1252
Metrics as of 6 Oct 2026. Not real time.
Track Ipca Laboratories Ltd
Cruxal reads every Ipca Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Ipca Laboratories Ltd growth and returns
- 10 Years
- 13%
- 5 Years
- 12%
- 3 Years
- 16%
- TTM
- 11%
- 10 Years
- 30%
- 5 Years
- 1%
- 3 Years
- 37%
- TTM
- 54%
- 10 Years
- 20%
- 5 Years
- 11%
- 3 Years
- 28%
- 1 Year
- 47%
- 10 Years
- 14%
- 5 Years
- 13%
- 3 Years
- 13%
- Last Year
- 16%
Ipca Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹2,788 cr, up 20.7% from ₹2,309 cr a year earlier. Net profit was ₹424 cr, up 82.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 | 2,392 | 2,388 | 2,788 |
| Expenses | 1,913 | 1,782 | 1,818 | 1,892 | 2,012 | 1,859 | 1,905 | 2,119 |
| Operating profit | 441 | 463 | 429 | 416 | 545 | 533 | 484 | 670 |
| OPM % | 19% | 21% | 19% | 18% | 21% | 22% | 20% | 24% |
| Other income | 26 | 20 | -179 | 33 | -30 | 38 | 48 | 25 |
| Interest | 23 | 17 | 22 | 19 | 20 | 18 | 20 | 12 |
| Depreciation | 100 | 98 | 100 | 100 | 103 | 108 | 107 | 111 |
| Profit before tax | 345 | 368 | 128 | 331 | 392 | 446 | 404 | 572 |
| Tax % | 29% | 25% | 49% | 29% | 28% | 18% | 24% | 26% |
| Net profit | 246 | 276 | 64 | 233 | 281 | 364 | 307 | 424 |
| EPS (₹) | 9.05 | 9.78 | 2.67 | 9.19 | 11.14 | 12.86 | 11.79 | 15.84 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Ipca Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,156 | 3,258 | 3,746 | 4,619 | 5,395 | 5,797 | 6,204 | 7,662 | 8,897 | 9,599 | 10,126 |
| Operating profit | 451 | 455 | 695 | 904 | 1,552 | 1,325 | 932 | 1,324 | 1,731 | 1,990 | 2,232 |
| OPM % | 14% | 14% | 19% | 20% | 29% | 23% | 15% | 17% | 19% | 21% | 22% |
| Net profit | 195 | 239 | 442 | 604 | 1,141 | 890 | 479 | 523 | 785 | 1,184 | 1,375 |
| EPS (₹) | 7.71 | 9.49 | 17.60 | 23.99 | 44.94 | 34.85 | 18.58 | 21.57 | 29.08 | 44.98 | 51.63 |
TTM is the trailing twelve months to the most recent quarter.
Ipca Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 2,430 | 2,663 | 3,097 | 3,602 | 4,676 | 5,467 | 5,817 | 6,307 | 6,923 | 8,038 |
| Borrowings | 716 | 628 | 465 | 501 | 265 | 807 | 1,481 | 1,438 | 1,363 | 809 |
| Other liabilities | 788 | 799 | 961 | 1,130 | 1,099 | 1,338 | 1,300 | 3,326 | 3,432 | 3,477 |
| Total liabilities | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,637 | 8,623 | 11,097 | 11,744 | 12,350 |
| Fixed assets | 1,983 | 1,953 | 1,940 | 2,059 | 2,072 | 2,418 | 2,751 | 4,554 | 4,267 | 4,627 |
| CWIP | 95 | 73 | 66 | 133 | 235 | 306 | 140 | 343 | 622 | 773 |
| Investments | 136 | 87 | 120 | 310 | 505 | 989 | 626 | 862 | 980 | 844 |
| Other assets | 1,746 | 2,003 | 2,422 | 2,756 | 3,254 | 3,924 | 5,105 | 5,339 | 5,875 | 6,106 |
| Total assets | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,637 | 8,623 | 11,097 | 11,744 | 12,350 |
As reported by the company. Total assets equal total liabilities by construction.
Ipca Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 282 | 341 | 501 | 570 | 1,090 | 856 | 806 | 945 | 1,321 | 1,142 |
| Cash from investing | -149 | -135 | -165 | -509 | -521 | -851 | -725 | -1,215 | -870 | -247 |
| Cash from financing | -159 | -130 | -183 | -137 | -306 | 427 | 507 | -553 | -283 | -754 |
| Net cash flow | -26 | 75 | 153 | -76 | 264 | 432 | 588 | -823 | 169 | 142 |
| Free cash flow | 147 | 206 | 322 | 277 | 731 | 380 | 347 | 543 | 551 | 486 |
| CFO / operating profit | 74% | 88% | 88% | 80% | 86% | 80% | 110% | 94% | 97% | 78% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Ipca Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 9% | 10% | 16% | 19% | 31% | 20% | 11% | 13% | 15% | 17% |
| Debtor days | 58 | 67 | 66 | 71 | 55 | 57 | 58 | 80 | 77 | 77 |
| Inventory days | 290 | 286 | 316 | 294 | 337 | 337 | 276 | 350 | 336 | 353 |
| Days payable | 130 | 137 | 154 | 135 | 140 | 101 | 83 | 110 | 111 | 122 |
| Cash conversion cycle | 218 | 216 | 228 | 229 | 251 | 293 | 251 | 321 | 302 | 308 |
| Working capital days | 74 | 80 | 88 | 88 | 103 | 102 | 71 | 111 | 101 | 109 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Ipca Laboratories Ltd shareholding pattern
Promoters held 44.72% at Jun 2026, broadly unchanged since Jun 2025. FIIs 10.72% and DIIs 37.04%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 46.30% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% |
| FIIs | 10.83% | 11.06% | 10.75% | 10.67% | 10.42% | 10.62% | 10.63% | 10.72% |
| DIIs | 33.90% | 35.36% | 35.73% | 35.88% | 36.45% | 36.99% | 37.13% | 37.04% |
| Government | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% |
| Public | 8.64% | 8.53% | 8.45% | 8.41% | 8.09% | 7.33% | 7.21% | 7.19% |
| No. of shareholders | 82,975 | 90,189 | 88,306 | 85,582 | 82,870 | 77,673 | 82,184 | 82,060 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Ipca Laboratories Ltd corporate filings
- Closure of Trading WindowInsider Trading / SASTlow impact
- Ipca Laboratories Ltd releases transcript of conference call held on August 17, 2026Company Updatelow impact
Cruxal's analysis: Ipca Laboratories has filed the transcript of its analyst/investor conference call…
Read the full analysis - Ipca Laboratories Ltd releases audio recording of investor conference call held on August 14, 2026Company Updatelow impact
Cruxal's analysis: Ipca Laboratories has made the audio recording of its investor and analyst conference…
Read the full analysis - Ipca Laboratories Ltd: Publication of Financial Results in NewspapersCompany Updatelow impact
Cruxal's analysis: Ipca Laboratories Ltd has fulfilled its regulatory obligation under Regulation 30 of the…
Read the full analysis - Ipca Laboratories Limited Announces Successful Conclusion of 76th Annual General Meeting and Shareholder Approval of All ResolutionsAGM/EGMlow impact
Cruxal's analysis: Ipca Laboratories Limited has successfully concluded its 76th Annual General Meeting held…
Read the full analysis - Ipca Laboratories Limited concludes 76th Annual General Meeting; routine business and director re-appointments processedAGM/EGMlow impact
Cruxal's analysis: Ipca Laboratories Limited has successfully concluded its 76th Annual General Meeting held…
Read the full analysis - Ipca Laboratories Q1 FY27 Results: Strong Performance with 72% YoY Consolidated Net Profit GrowthBoard Meetinghigh impact
Cruxal's analysis: Ipca Laboratories Limited reported robust Q1 FY27 financial results, with consolidated…
Read the full analysis - Ipca Laboratories schedules Q1 FY27 earnings conference call for August 14, 2026Company Updatelow impact
Cruxal's analysis: Ipca Laboratories Limited has announced that it will host an earnings conference call on…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.